IL17A and bacterial infectious disease with sepsis: Concerning safety, pooled data across these clinical trials indicated that treatment with IL-17 inhibitors leads to a higher risk of curable non-fatal infection but not other severe adverse events, such as serious infection and infestation (including reactivation tuberculosis, bacterial sepsis, and invasive fungal infections) or death.